Daiichi Sankyo and AstraZeneca’s Enhertu gains NMPA approval for HER2 GEJ
The approval is supported by data from the DESTINY-Gastric04 Phase III trial.
Drug Development
Opna Bio’s OPN-2853 secures FDA’s orphan drug status for myelofibrosis
BMS and Microsoft partner for AI-based lung cancer detection
Novo Nordisk and Aspect Biosystems advance partnership for diabetes therapies
iRegene receives FDA RMAT designation for NouvNeu001 to treat Parkinson’s
AstraZeneca to acquire China rights for AbelZeta’s CAR-T therapy
FDA grants Novartis’ ianalumab breakthrough therapy status for Sjögren’s disease
InterAx and Alveus collaborate on small-molecule metabolic treatment
